BEIJING, April 19 (silubaba) -- China's drug bulk-buying program for insulin products has resulted in an average price cut of 48 percent, benefiting over 10 million people with diabetes, according to the National Healthcare Security Administration.
The scheme was rolled out last May, marking the first time that biopharmaceuticals were included in the national centralized drug procurement program. The procurement covered 42 second- and third-generation insulin products commonly used in clinical treatments.
In China, the number of diabetes patients aged between 20 and 79 was 140 million in 2021, and the figure is expected to reach 164 million by 2030, statistics from the International Diabetes Federation showed. ■
微信扫描下方的二维码阅读本文
